Certara (NASDAQ:CERT) Trading Down 4.8% on Analyst Downgrade

Certara, Inc. (NASDAQ:CERT)’s stock price dropped 4.8% on Tuesday after KeyCorp lowered their price target on the stock from $18.00 to $15.00. KeyCorp currently has an overweight rating on the stock. Certara traded as low as $10.65 and last traded at $10.60. Approximately 207,751 shares were traded during trading, a decline of 86% from the average daily volume of 1,474,408 shares. The stock had previously closed at $11.14.

CERT has been the topic of a number of other research reports. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. Morgan Stanley started coverage on shares of Certara in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price for the company. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.29.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after purchasing an additional 38,068 shares during the period. ArrowMark Colorado Holdings LLC grew its stake in shares of Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after acquiring an additional 3,861,674 shares during the period. Geneva Capital Management LLC increased its holdings in Certara by 3.9% in the 1st quarter. Geneva Capital Management LLC now owns 5,671,689 shares of the company’s stock worth $56,150,000 after acquiring an additional 213,089 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Certara by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock worth $48,542,000 after acquiring an additional 557,348 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Certara by 13.6% during the 1st quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock worth $42,526,000 after acquiring an additional 515,911 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

The firm has a market cap of $1.69 billion, a PE ratio of -520.50 and a beta of 1.43. The firm’s fifty day simple moving average is $11.37 and its two-hundred day simple moving average is $11.87. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. Certara’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.